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            Section 505(b)(2) of the Food, Drug, and Cosmetic Act (FDCA) (“505(b)(2)”), a 
component of the 1984 Hatch-Waxman Amendment allows the Food and Drug Administration 
(FDA) to rely on evidence not owned by the applicant. When combined with Section 115(a) of 
the Food and Drug Administration Modernization Act of 1997 (“Section 115(a)”), which allows 
for approvals to be based on one study and confirmatory evidence, clinical development 
programs can be streamlined, particularly during the 'Lifecycle' portion of the drug development 
program. This term is typically applied to the phase of development following the initial 
approval of the active moiety for products that often include modified-release or fixed-dose 
combination drugs. 
            To further understand the strategies used in 505(b)(2) submissions, a database of 
informative variables describing the drug, applicant, and development program was created by 
abstracting information related to the development programs from publicly available Summary 
Basis of Approvals (SBOAs). Analyses were performed using descriptive statistics on the dataset 
as a whole, and by investigating intra-class differences, based on variables such as chemical and 
therapeutic classification. The findings from this study provide knowledge on critical points in 
development programs, and identify potential areas for improvement that may lead to an increase 
in efficiency for these processes. 
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II. Introduction  
The burden of lifecycle development for a drug includes not only the time and resources 
to execute pharmacology/toxicology studies, clinical pharmacology studies and clinical trials, but 
also that which is needed to support the application and review cycles after submission of the 
New Drug Application (NDA)1. The data in the submission must provide evidence of safety and 
efficacy for the proposed new drug. These requirements emerged only in the last century, despite 
drugs being sold in America since the formation of the colonies (Authentichistory.com, 2012). 
The 1938 passage of The Food, Drug, and Cosmetic Act (FD&C Act) marked the first time that 
drug manufacturers were required to provide pre-approval safety data. Demonstration of efficacy 
and the need for trial replication was not required until the passage of the Kefauver-Harris 
Amendments to the FD&C Act in 1962 (U.S. Food and Drug Administration, 1999). This 
mounting requirement for data prior to approval for marketing was largely attributed to tragic 
episodes. These episodes included the deaths of many children because of the particular vehicle 
used in an antimicrobial prior to the FD&C Act, and the malformation of children from the use 
of thalidomide during organogenesis, prior to the passage of the Kefauver-Harris Amendments 
(Woosley, 2012).  
Several regulatory initiatives have served to reduce the workload of the pharmaceutical 
industry and expedite the development of drugs, while also maintaining the level of necessary 
evidence necessary for approval since the passage of the Kefauver-Harris Amendments. Before 
1984, the FDA employed a paper NDA policy allowing approval of a NDA to be granted based 
                                                
1NDA will be used to generally refer to any premarketing application, whether for a drug or biologic 
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on literature and drug-specific information (this was mostly relevant to generic drugs). The 1984 
Hatch Waxman Amendments expanded this policy, allowing for approval of NDAs based on 
literature and drug specific information not owned by the applicant (FDA, 1999). In the wake of 
the growing AIDS epidemic, the Prescription Drug User Fee Act (PDUFA) was passed in 1992, 
to expedite the drug review process. A major goal of PDUFA was to provide a constrained 
timeline for the review of marketing applications. In addition to setting timelines for the review 
of standard drugs, more recent cycles of PDUFA have given rise to programs to expedite the 
development and review cycle, such as Breakthrough Drugs, Priority Review, Accelerated 
Approval, and the Fast Track pathway (FDA, 2012). Over a decade later, in 1997, The Food and 
Drug Administration Modernization Act (FDAMA) was amended to include that “Substantial 
Evidence” of effectiveness may be determined to be adequate based on data from one clinical 
trial and confirmatory evidence (Section 115(a) FADAMA). Prior to FDAMA following the 
Kefauver-Harris amendments, the required level of evidence, as defined in Section 505(d) of the 
Act, stated that investigations (emphasis on the plural "s") were needed, implying that two 
adequate and well-controlled trials would be required to replicate the evidence. In the 
Modernization Act, Congress amended section 505(d) of the Act to allow that "...substantial 
evidence may, where there is a high level of confidence in the scientific validity of the results of 
an adequate and well-controlled investigation, consist of data from an adequate and well 
controlled investigation and adequate supportive scientific evidence…", the latter often being 
termed ‘Contributory evidence’. 
Another major change to the development and review process came about in 2008 when 
the Food and Drug Administration (FDA) replaced the Approvable/Not Approvable actions with 
a Complete Response action at the end of the review period. This allows applications that may 
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have previously been found Not Approvable because of deficiencies, to be resubmitted as a 
remedied application and continue to seek approval (FDA, 2008). 
 The process of submitting an NDA can be confusing, even when using a standard 
‘unabridged’ strategy (no Expedited Programs, or 505(b)(2) process). There are few resources 
and studies available to aid applicants and regulators that collectively describe the regulatory 
precedents, especially the evidence needed to support the approval of 505(b)(2) NDAs. These 
requirements for contributory evidence may vary greatly depending on a variety of factors, 
including, the results of prior PK, pharmacology and clinical studies and the drug, indication, and 
intended population. This study will examine the contributory and substantial evidence needed 
for NDAs submitted under 505(b)(2) of the FD&CA. A systematic review of the trends in the 
recent regulatory approvals of 505(b)(2) applications will provide a useful and fact-based 
foundation for discussion between applicants and the agency. 
III. Literature Review 
Literature on pharmaceutical regulatory strategy often notes the importance of gathering 
information on the drug development lifecycle (Kwok, 2015). Recent publications have focused 
on issues such as the duration of approval time, contributing factors to delays in the approval 
process, and an overall lack of understanding surrounding the drug development process (Kwok 
2015, Agarwal 2014). Furthermore, when considering strategies that capitalize on the regulations 
enacted to make the process more efficient, the literature brings forth additional unique 
problems, such as what is needed to shorten approval time and whether or not shorter approval 
times are beneficial. It also illuminates areas in need of further clarification, such as the level of 
substantial evidence required for approval.  
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There has been considerable discussion in the literature on submissions of NDAs that 
satisfy the application requirements via pathways other than the ‘traditional’ Nonclinical, 
Clinical Pharmacology, and two Adequate and Well-controlled clinical Trials (AWT). Much of 
this discourse is aimed at providing further clarification regarding these routes, as they range 
from drugs in Expedited Programs, to drugs that reference literature or the Agency’s past safety 
and efficacy findings. A review of these non-traditional routes will clarify how these strategies 
can help to reduce the cost of development, shorten the approval times, and potentially modify 
the burden of lifecycle development. 
The FDA has made major contributions to the body of literature surrounding this topic in 
the form of guidances that highlight the historical changes in the drug development process. 
These guidances clearly outline the evolution of how contributory evidence can support 
approval. The FDA Guidance “Providing Clinical Evidence of Effectiveness for Human Drug 
and Biological Products” (also known as the “Effectiveness Guidance”) released in 1998, 
provides helpful recommendations to the industry regarding criteria for Substantial Evidence. An 
essential role of the Effectiveness Guidance was to clarify FDAMA’s modification of Section 
505(d) of the Act, by emphasizing that there were instances in which one AWT along with 
contributory evidence could be sufficient to provide substantial evidence for effectiveness. 
Considering that the costs of trials increase as a drug progresses through the development 
lifecycle, it is not surprising that trials used to demonstrate efficacy in an NDA (sometimes 
referred to as Phase 3) are so expensive (Sertkaya, 2014). With the average cost of developing a 
drug currently estimated to be around 800 million U.S. dollars (DiMasi, 2010) and rising 
(Sertkaya, 2014), any cost savings or resource conservation measures that can be implemented to 
lower the cost of development have the potential to realize savings that could ultimately reduce 
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the cost of drugs for patients. The Effectiveness Guidance provides great utility to industry by 
explaining how to properly interpret the FD&CA amendments to reduce the burden of the 
clinical development. Reed (2007) takes a different approach to assessing the increased burden 
of drug development by incorporating the resource of drug approval time into the optimization 
rule they developed for use by pharmaceutical firms. However, both discussions fail to fully 
account for the actual value of the drug, which could lead to an uninformed decision. 
Coutant and his colleagues (2010) lay out the following three scenarios for approvals 
based on less than two AWTs. 1. Substantial evidence proven via extrapolation from existing 
studies or from new comparative PK bioavailability trial (no new AWT required), 2. A single 
AWT with independent substantiation from related clinical data, and finally, 3. Reliance on a 
single multi-center study, without supporting information (single AWT). Given the inevitable 
variations within each of these broad scenarios, the composition of Substantial Evidence must be 
unique for each application. Considering that the majority of 505(b)(2) applications employ the 
latter two strategies, it is easy to understand why articles on the 505(b)(2) strategy can only give 
a vague idea as to the extent to which reference information can be used to support the 
application, and what additional information will be needed with it to complete the application. 
In his commentary on this issue, Hurley (2004) is left to simply recommending a discussion with 
the Agency Division conducting the Applicant’s review.  
When considering regulatory strategies, the 505(b)(2) NDA pathway is commonly 
utilized for non-New Molecular Entities (non-NMEs). Hurley (2004) notes that, early on, the 
505(b)(2) route of approval was unpopular, with only 126 drugs approved via this route between 
1984 and 2004. As with the other strategies for expediting development, it has gained popularity 
in recent years (Agarwal, 2014). In contrast to the findings of Hurley (2004), consider that 
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Agarwal (2014) found that 132 505(b)(2) New Drug Applications were filed during the three-
year period from January 2010 to December 2012. Agarwal (2014) observed that number of 
505(b)(2) NDAs from 2010 to 2012 was higher than the number of New Molecular Entity NDAs 
submitted for approval. 
The limited body of literature on 505(b)(2) applications consists of primarily papers that 
focus on only one of the specific areas of the drug development lifecycle, such as clinical 
pharmacology (Agarwal, 2014). Although these papers are helpful in gaining detailed 
information and insight into a portion of the process, they fail to reveal the larger picture, often 
leaving out the intricate interplay between these factors. Additionally, focus on a single area of 
the drug development process can often result in the omission of important factors, such as the 
operational aspects of clinical trials or clinical supply chain, which can often be the most 
expensive and resource consuming aspect of development (DiMasi, 2010). 
The 505(b)(2) pathway has provoked some controversy within the pharmaceutical 
industry. There have been lawsuits surrounding patent infringement, similar to what is 
encountered with the generic approval process. The best example of this controversy may be the 
petitions filed by Pfizer Inc. and Pharmacia Corporation in an attempt to overturn the 505(b)(2) 
policy. In response to these petitions, the Generic Pharmaceutical Association (GPhA) 
maintained that Section 505(b)(2) was added to incentivize the research and development of 
improving current drugs, to eliminate duplicative studies, and to expedite the lifecycle 
development of these drugs, potentially reducing their cost. 
In response to recent pleas to shorten approval times for new drug applications (NDAs), 
new Expedited Programs have been created as recently as 2012. As discussed in the background, 
these Expedited Programs can either change what is needed to fulfill the application 
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requirements, as is the case with Orphan designation and Accelerated Approval, or provide a 
means to facilitate either the development or the review process, as is the case with the other 
Expedited Programs. Although these programs are more commonly utilized via the 505(b)(1) 
pathway, they are sometimes also used for a 505(b)(2) NDA. The importance of these programs 
is underscored by the rise in popularity of Expedited Programs. Kesselheim (2015) notes that 
56% of all New Molecular Entities approved from 2002 to 2013 benefitted from at least one 
Expedited Program. The study also notes the increase in the number of New Molecular Entities 
benefiting from more than one Expedited Program, beginning at less than 20% in 1987 and rising 
to over 40% in 2013. 
There has been some debate over the effectiveness of certain Expedited Programs in 
shortening the drug development lifecycle. While this is not expected to be an issue that greatly 
affects the 505(b)(2) submission route, the data in this study reveal that this is an important topic. 
As Sasinowski (2011) reports with respect to the Orphan drug designation, this can be difficult to 
substantiate, due to the flexibility in Expedited Programs and the number of factors that must be 
considered when evaluating the time to approval. One study found no difference in review time 
for Accelerated Approval vs. standard review time (Benson, 2011), while others claim that drugs 
within the expedited approval process benefit from shorter review periods, as well as shortened 
development periods (Kesselheim 2015, Kwok 2015). An example given by Kesselheim (2015) 
is the drug imatinib (Gleevec). This drug reportedly benefited from Fast Track, Accelerated 
Approval, and Priority Review designation, leading to the completion of its review in 2.5 
months. Kwok’s 2015 review of this issue discusses the many factors that go into the approval 
process, and outlines those that can often cause delays in the development lifecycle of drugs 
when Expedited Programs are utilized. These factors often arise as unforeseen problems in the 
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production process, such as deficiencies in the inspection of manufacturing sites (Kwok, 2015). 
Kwok (2015) also suggests that the rush to complete certain aspects of the development lifecycle 
within the auspices of Expedited Programs may cause some of these deficiencies to arise.  
A major focus of the drug development literature deals with the duration of the time to 
approval, including the duration of the regulatory review period. There is little documented data 
on this topic in regards to the 505(b)(2) application route, despite the topic’s importance to the 
overall pharmaceutical industry, and its often ill effects on the public opinion of the 
pharmaceutical industry and the FDA. One of the more controversial positions discussed in the 
literature related to time to approval is that approval times are faster outside than within the 
United States. This viewpoint has gained a deal of popularity due to recent legislation, such as 
the Speeding Access to Already Approved Pharmaceuticals Act proposed to congress in 2014 
(H.R. 4918, 2014) and then again in 2015 (H.R. 4918, 2015). Contrary to the ideas perpetuated 
by the majority of the media coverage on this issue, and the pressures put on the FDA by 
politicians who pontificate on the need for shorter approval times (Kulynych, 1999), the data 
suggest otherwise. Downing et al (2012) study published in the New England Journal of 
Medicine compared the regulatory review times of the United States (FDA) with the regulatory 
bodies in Europe (EMA) and Canada (Health Canada). The study found that from 2001 to 2010, 
the FDA approved more drugs (225) than the EMA (186) or Health Canada (99). Downing et al. 
also reported that the FDA approved drugs with shorter average review times (303) than either 
the EMA (366) or Health Canada (352). Other studies support these findings by demonstrating 
that the FDA approved 63.7%, and 85.7% of drugs faster than Europe or Canada (respectively) 
(Kesselheim 2015, Benson 2011).  
 Shorter review times have given rise to concerns in regards to safety. Kesselheim (2015) 
 
9	
reports that studies have found a 35% increase of a black box warning on Orphan drugs. Others, 
however, report no inverse correlation between an increase of adverse events and a decrease in 
review time. Spielmans and Kirsch (2014) raise the concern that the public is generally unaware 
of the relatively low bar for effectiveness that the FDA has set for the approval.  
IV. Problem Statement 
The Literature Review reveals that little research has focused on the benefits and track 
records of development programs that employ the 505(b)(2) pathway. This project will explore 
issues relevant to the regulatory burden mentioned in the Literature Review, such as approval 
time, causes of delays, and level of evidence required for approval. It will also fill gaps in our 
understanding left by the current literature, and allow the reader to grasp a much broader picture 
of pharmaceutical lifecycle management. A thorough and comprehensive view of the problem 
areas from data collected from individual applications in the pharmacology/toxicology, clinical 
pharmacology and clinical reviews provides a perspective unavailable from the current literature. 
V. Specific Aims 
A. Primary Objective 
To identify predictive patterns in demographic factors (e.g., related to the applicant, 
regulators, drug, indication) that are associated with different levels of regulatory evidence (e.g., 




B. Secondary Objectives  
To identify characteristics of 505(b)(2) programs associated with regulatory success (e.g., 
shorter development times), delays, or failure (e.g., Complete Response actions). 
VI. Methods 
A. Strategy of the Review and Analysis  
A list of NDAs approved by the 505(b)(2) pathway was compiled from the information 
available at the NDA and BLA Calendar Year Approval website (FDA, 2016b). Summary Basis 
of Approval documents (SBOAs) were downloaded from the Drugs@FDA (FDA, 2016a) 
database for 505(b)(2) applications approved between 2010 and 2015. SBOAs were reviewed, 
prioritizing the most recently approved applications and including all of the available SBOAs 
from 2014 and 2015. The SBOAs were abstracted to identify ‘Demographic Variables’ that 
describe the drug (e.g., ATC2 Code) or regulatory process (e.g., Review Division or whether the 
program received a Complete Response), and ‘Content Variables’ that describe what was 
included in the Nonclinical, Clinical Pharmacology, and Clinical aspects of the application (e.g., 
subject numbers for clinical studies). To gain a perspective on the development programs that 
were abstracted, Demographic and Content Variables were summarized in terms of the following 
Key Subpopulations: 
• Year of approval  
• Chemical Classification – the FDA classification system that describes how new the 
classified drug is based on whether it itself is a new formulation or it is a new indication 
for an existing drug formulation (FDA, 2015) 
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• Purpose of 505(b)(2) application – A classification developed for the purposes of this 
project, describing the modification of the drug from any reference drug in terms slightly 
more granular than the Chemical Classification 
• ATC 2 Code - Part of the Anatomical Therapeutic Chemical Classification System used 
to classify active components of a drug, based on the main therapeutic group (WHO 
Collaborating Centre for Drug Statistics Methodology, 2013) 
• Therapeutic Class – A classification developed for the purposes of this project describing 
the therapeutic use of the drug 
Of the Key Subpopulations, the Year of Approval was used to assess any evolving trends in the 
landscape of 505(b)(2) submissions over time. Chemical Class and Purpose of 505(b)(2) 
Application were the best representation of what drove the application (“application drivers”). 
ATC2 Code and Therapeutic Class were chosen as the best descriptors of the clinical utility of 
the drug.  
The Key Subpopulations were used in the primary analyses, forming the foundation of 
the analysis plan. Subpopulation analysis with other variables or in addition to the Key 
Subpopulations was done to further assess the strategies and outcomes of the Applications and to 
explore the associations suggested in the primary analysis. 
B. Methodology  
1. Data Acquisition  
The 505(b)(2) Database was compiled from a listing of 505(b)(2) programs from the 
website (FDA, 2016b) Food and Drug Administration / NDA and BLA Calendar Year Approvals 
(last access date: 5/1/16) from 2010 to 2015. SBOAs were preferentially reviewed from 2014 
and 2015 with random sampling of applications from 2010 to 2013. The focus on the most recent 
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years was to provide a sample with the most up to date and current picture of the information that 
was being submitted to and reviewed/approved by the agency. Demographic and outcome 
characteristics from drug development programs were first identified. The majority of the 
variables were added very early on, or before beginning the data collection process, but to ensure 
no new variables were missed, throughout the process when new variables were encountered 
they were documented in an “other additional studies” column. During the weekly review 
process discussion of the prevalence of certain “other additional studies” occasionally resulted in 
the addition of variables to the database, in other words, removing “study x” from the “other 
additional studies” and making “study x” its own additional column. Once the demographic and 
outcome characteristics from drug development programs were identified they were then entered 
into an EXCEL database by a primary reviewer. Certain variables were entered as Y/N, others 
were numeral, and others were acronyms (text) or free text (see appendix A for the full list). 
Some of the variables pertained to the timeline of the application and were later combined to 
create new variables defining the length of time between important drug development milestones 
or regulatory actions throughout the application approval process. 
All fields of the database were verified during a second review period. Additionally, 
weekly progress meetings were held to discuss any concerns or situations needing clarification, 
as well as to review the completed work (having had both the first and second review processes 
completed) from the week. Any disagreements found between the first and second review 
process were discussed and decided during group meetings. Once the review of SBOAs was 
completed, an audit of all variables relevant to this analysis was conducted to verify and attempt 
to find any missing information. The auditing process ensured consistency in the formatting of 




2. Analysis  
The primary analyses were developed prospectively, prior to the completion of the data 
collection. The key endpoints for each of the demographics used in the primary analysis were as 
follows: 
• Average Number of Studies Required for Substantial Evidence 
• Sources of Contributory Evidence 
• Subjects in the Phase 2b/3a and Total Development Program 
• Complete Responses and Review Extensions 
• Waivers and Post-Marketing Requirements 
Additional demographic and outcome characteristics in the Nonclinical, Clinical 
Pharmacology and Clinical areas of the application were used in further subpopulation analyses 
of each of the demographics factors in the first level analysis. Means and standard deviations 
were derived from JMP software.  
The variables pertaining to date and timeline information collected from the application 
were combined to create the following new variables, defining the length of time between 
important drug development milestones or regulatory actions throughout the application approval 
process. (see appendix A) 
- Duration of the Lifecycle Development Program: Approval Date – Initial IND Submit 
Date 
- Duration of the Regulatory Review Cycle: Approval Date – Final NDA Submit Date  
- The Delay Period: Final NDA Submission Date – Initial NDA Submission Date 
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VII. Results and Discussion 
A. Database Description 
The final dataset included information from 100 SBOAs reviewed for 135 unique 
variables and contained 44 ‘demographic’ features and 91 ‘content features’. Of the content 
features 31 were Nonclinical, 32, Clinical Pharmacology, and 28, Clinical (Figure 1).  
Figure 1, Variable Breakdown 
 
The database consisted of 13,500 unique data cells, of which 150 cells were missing from 
11 different variables. Thirty two total data points from eight different variables were marked as 
unknown.  
Descriptive statistics for the unique variables were further evaluated by performing 
subpopulation analyses for the following five key variables:    
1. Year of Approval   
 
The final dataset of 100 SBOAs (or N = 100), included all of the available SBOAs from 
2014 (N = 32) and 2015 (N = 32). The remaining 36 SBOAs reviewed were from between 2010 
and 2013; 18 were from 2013, 9 were from 2012, 3 were from 2011, and 6 were from 2010. The 
strategy behind this selection was to review the most recent applications to provide the most up 
 
15	
to date and current information on the landscape of the 505(b)(2) applications being submitted 
for approval. Additionally, the random sampling from past years was considered an important 
tool in tracking the trends of the changing landscape over time. 
Figure 2, Distribution of SBOAs by Year of Approval 
 
Total Number of SBOAs reviewed N = 100 
 
2.  Chemical Class 
 
Figure 1 displays the distribution of the 100 SBOA database by the variable, Chemical 
Classification. The top three Chemical Classes accounted for 81% of the total number of 





Figure 3, Percentage of Applications by Chemical Classification 
 
Total number of applications reviewed, N=100 
These groups include previously approved drug products, allowing for extra value to be 
generated from the innovator drug for the original applicant, and a portfolio with less regulatory 
risk for companies that do not have the resources to bring drugs through discovery to the market.  
3. Purpose of 505(b)(2) Application 
 
The variable, Purpose of the 505(b)(2) Application, was developed for this project and 








             Figure 4, Distribution of SBOAs by Purpose of 505(b)(2) Application 
 
     Total number of applications reviewed, N = 100 
 
New Formulation was the most popular of these groups, containing 47% of the 
applications, more than triple the number of applications represented in any other category. 
Combination of 2 Approved (C2A), is one of 4 categories describing different types of 
combination drugs (e.g. combination of 1 approved and 1 NCE, CAN; or Combination 3 
Approved, C3A) and was the second most common category with 15% of the applications. 
Altogether, the four categories describing combination drugs account for over one fifth (21%) of 
the applications. The third and fourth most common categories were Modified Release (13%), 
and Marketed Unapproved (10%) drugs with the remaining categories representing fewer than 
10% of the applications. Notably, three categories representing different iterations of NME or 
NCE represent 6% of the applications. 
The breakdown of the Purpose of the 505(b)(2) Application helps to identify some major 
pathways/themes of utilization of these applications. Beyond identifying the popularity of the 
various themes discussed above, the Purpose of the 505(b)(2) Applications categories 
demonstrates the types of variation seen within each of these themes. This will be covered in 
greater depth later on, during the discussion concerning the utilization and adaptability of the 
505(b)(2) application route. 
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4. ATC2 Code  
 
The ATC2 Code is akin to a standardized and internationally recognized Therapeutic 
Class and can provide insight into the variety of drugs currently approved indications. Of the 46 
unique ATC2 Codes identified (listed in appendix B), four ATC2 Codes contained 6 or more of 
the applications, which when combined accounted for 29% of the total number of applications. 
The most common ATC2 Codes were Antibacterials for Systemic Use and Antineoplastic 
Agents, each with 8% of the applications, followed by Psychoanaleptics (7%), and 
Ophthalmologicals (6%).  
Table 1, Most Commonly Encountered ATC2 Codes 
ATC 2 Code Number of Applications (Descending Order) 
Antibacterials for Systemic Use 8 




The large number of ATC2 Codes represented in the dataset is partly due to the utility of 
the 505(b)(2) application making it especially useful as a resource in portfolio management, 
which will be discussed in further detail in the following Section (VII.B.1). 
5.  Therapeutic Class  
 
Therapeutic Class was developed for the purposes of this project, and provided an 
opportunity to cluster applications in meaningful but less granular groups than the ATC2 Code. 
Of the 45 Therapeutic Classes represented in the dataset (listed in appendix C), three categories, 
Analgesics (11%), Antibiotics (10%), and Antineoplastics (8%) contained eight or more 





Table 2, Most Commonly Encountered Therapeutic Classes 





Similar to what was seen with ATC2 Codes, the absence of a single prevalent 
Therapeutic Class application demonstrates the wide range of clinical applications for 505(b)(2) 
drugs providing opportunities in all areas of development. 
B. Characteristics of Drugs Approved Under 505(b)(2) of the Food Drug and 
Cosmetic Act 
 
The sections that follow are a systematic description of the results analyzed from the 
perspective of the key subpopulation variables.   
1. Portfolio and Risk Strategy  
A pharmaceutical portfolio is optimized by balancing, financial returns with regulatory 
and scientific risk, as well as the timing of resource consumption for assets being developed in  
parallel. In this section, data from the database is used to support the concept that integrating  
drugs approved by the 505(b)(2) pathway into the portfolio offers certain advantages over a  
 
pipeline entirely composed of NCEs utilizing the 505(b)(1) pathway.  
 
a) More Information Available on Safety and Efficacy  
 
The 505(b)(2) application allows for referencing a prior drug approval’s finding of safety 
and efficacy. This is the most common type of reference with at least 88% of the applications 




Table 3, Number of Applications Per Reference Type by Nonclinical, Clinical Pharmacology, 
and Clinical 
Reference Type Nonclinical Clinical Pharmacology Clinical 
Prior Findings of Safety and Efficacy 65 70 64 
Literature + Prior Findings of Safety and 
Efficacy 15 14 14 
Monograph + Prior Findings of Safety and 
Efficacy 4 4 2 
Literature  11 9 10 
Literature + Monograph 1 0 0 
Monograph 1 1 0 
None  1 2 10 
*Unknown 2 0 0 
**Total Number Referencing Prior 
Findings of Safety and Efficacy (Alone or 
in Combination) 
84 88 80 
*The “Unknown” designation refers to applications for which the information was unable to be determined 
**This row refers to the total number of applications referencing Prior findings of safety and efficacy, either alone 
or in combination with another reference type, this row was formulated by adding the number of applications in the 
first three rows together.  
 
The prevalence of this type of reference speaks to the large amounts of data that has 
already been collected on the approved drugs. This type of reference reduces the development 
risk considerably because the risk benefit profile is known to a great extent, save for the 
contribution of the modification of the innovator drug. Because the reference drug has been on 
the market for some length of time already, additional safety data has been accumulated  over 
what was initially required for drug approval. As an example of the impact of this resource of 
information, 40% of the drugs in the Purpose for the 505(b)(2) Application analyses include 
combination drugs (Figure 4), and of these, 76% of the applications describe the combination of 
previously approved drugs. It is reasonable to infer that in the majority of the cases, the safety 
and efficacy of drugs approved by the 505(b)(2) pathway are likely to be better understood than 
drugs at the initial stage of their approval. 




Ninety percent of applications referenced Nonclinical, Clinical Pharmacology and 
Clinical information.  
Figure 5, Percentage of Total Applications Using a Reference by Nonclinical, Clinical 
Pharmacology, and Clinical 
 
Over 50% of the applications did not perform any Nonclinical (56%) or Clinical (58%) 
studies, suggesting that they were able to reference all of the necessary information for the 
respective category from previous sources, highlighting the copious reduction in regulatory 
burden attained by using the 505(b)(2) application route. The 505(b)(2) pathway helps to 
eliminate much of the industry’s unnecessary duplicate testing. This is a major resource drain for 
the pharmaceutical industry and was one of the problems the 505(b)(2) application route was 
created to solve. 
c) 505(b)(2) and Expedited Program Designation 
 
Pursuing a regulatory strategy based on Expedited Program designation as a portfolio-
strengthening option such as orphan drug designation (offering seven-years of exclusivity), or 
priority review (which is attributed to a shorter regulatory period) may come with a higher risk 
and less benefit than expected. 
The 505(b)(2) application route, like expedited programs, can be used as a portfolio-
strengthening strategy. In contrast to the Expedited Program designation tactic, which often 
relies on the importance and drama surrounding a “VIP” drug, the 505(b)(2) portfolio 
strengthening works by mitigating the risk and extensive resource expenditure of other programs 
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in the portfolio yet the 505(b)(2) application route may include drugs with Expedited Program 
designations, including the orphan drug designation. 
Twenty-one percent of applications included in the dataset were awarded at least one type 
of Expedited Program designation. Priority review and Orphan drug designation were the most 
common designations being awarded with 15%, and 10% of the applications respectively. Five 
percent of the applications received fast track designation and 1% received breakthrough 
designation. 
Concern surrounding uncertainty and risk have always been present in the pharmaceutical 
and biotechnology industries (Ebel, 2014), and is only expected to get worse in coming years as 
payers demand greater value and the low hanging fruit of G-protein coupled receptor agents is 
developed and goes generic. The ability of the 505(b)(2) application route to mitigate risk while 
still maintaining the possibility of participating in expedited programs makes this an ideal 
strategy to strengthen any pharmaceutical portfolio.  
C. Regulatory Burden 
1. Use of References  
Central to the 505(b)(2) pathway is the referencing of materials not owned by the 
applicant. The applicant must consider the use of reference material thoroughly since exclusivity 
time may be lost by not fully owning the materials in the NDA. Ninety-eight percent of SBOAs 
had Nonclinical and Clinical Pharmacology references, and 90% of SBOAs had Clinical 
references. The most common reference type was the Agency’s past safety and efficacy data 
across all the content categories. This is in contrast to the references to literature, which was only 
referenced by at least 27% of SBOAs, consisting of 27% of Nonclinical, 23% of Clinical 
Pharmacology, and 24% of Clinical NDA components (see Table 3 on page 28). The utility of 
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citing the Agency's previous findings is sound regulatory strategy because the data submitted for 
previous drug approval has already gone through the rigors of the Agency’s review criteria. The 
same claim cannot be made for all literature sources submitted as a reference. 
2. Studies Needed for Approval and Their Impact on the Timeline 
Performing studies to provide evidence to support an application can greatly change the 
burden of the lifecycle development program. The complexity of the studies generally increases 
(along with the cost) from Nonclinical to Clinical Pharmacology up to the most complex Clinical 
Trials. Forty-four applications completed at least one Nonclinical study, 77 applications 
completed at least one Clinical Pharmacology study, and 42 applications completed at least one 
Clinical study.  
Figure 6, Number of Applications Completing at Least One Study by 
        Nonclinical, Clinical Pharmacology, and Clinical 
 
The high percentage of applications performing Clinical Pharmacology studies is because 
a large portion of applications relied on the relative bioavailability study for approval. Often 
times this was not only the pivotal study need for approval, it was also the only study in the 
development program. This issue is discussed in further detail below. Figure 7 displays the type 
of evidence that was considered pivotal to the approval of the application by Chemical 
Classification, as specified by the reviewer of the application, 71 of the 100 SBOAs reviewed 
contained this information. 
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Figure 7, Absolute Number of Applications Relying on                                                   
Each Type of Pivotal Evidence by Chemical Classification 
 
     Abbreviations: AL: Adequate Literature; AWT: Adequate and Well Controlled Trial;  
     BW: Biowaiver; RB: Relative Bioavailability  
 
Chemical Class 1 drugs (New Molecular Entity) were the most likely to complete at least 
one Nonclinical or Clinical study and did so 70% and 73% of the time, respectively. Chemical 
Class 2 drugs (New Active) completed a Clinical Pharmacology study 100% of the time. Class 1 
and Class 2 drugs generally begin with less known information or studies than other classes of 
drugs. Therefore, it would be logical to assume that Class 1 and Class 2 drugs would be the most 
likely to perform studies in any of the content categories especially Clinical Trials, where the 
least information is likely to exist. 
Chemical Class 7 drugs (Marketed Unapproved) were the least likely to complete a 
Nonclinical, Clinical Pharmacology or Clinical study doing so 22%, 4% and 0% of the time, 
respectively. Marketed Unapproved drugs often have enough study data in the literature to 
support safety and efficacy, making this type of entity very attractive to sponsors. Only one of 
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the 100 SBOAs reviewed for this project, a Class 7 drug, was able to rely solely on literature 
references for approval (Figure 7). 
Overall the most common (21%) Nonclinical study completed by applicants was the 
Ames Test for mutagenicity. This is both expected, since the Ames test is one of the core 
requirements for submission of Investigational New Drug Applications in the United States, and 
surprising since most of the drugs in 505(b)(2) applications have been previously approved. The 
most commonly completed Clinical Pharmacology study was a Relative Bioavailability study, 
completed by 63% of the applications. The Relative Bioavailability study was the single most 
commonly conducted study, across all content categories. Of the 71 applications with 
information on pivotal studies over 33% (24 applications total) relied solely on a Relative 
Bioavailability study of the test drug and the reference drug for approval (see Figure 7, page 32).  
The most common Clinical study was a Phase 3a Clinical Trial (44%). A Phase 3a 
clinical study can provide the necessary efficacy information that may be harder to reference 
than safety information and, in some cases, the efficacy information may not exist for the 
applicant to be able to reference. Phase 2 studies may be less prevalent because the proof of 
concept or dose range may be based on prior approvals or the literature. 
Of the 100 SBOAs reviewed, there were three SBOAs that completed at least one 
Clinical Trial when it was not required (required meaning that it was seen as pivotal to the 
approval of the application). All three of the applications were Chemical Class 3 drugs. The two 
applications completing one clinical trial each were categorized as their Purpose for the 
505(b)(2) Application as Modified Release. The one Class 3 drug that completed two clinical 
trials when they were not required was categorized as a formulation change for the Purpose of 
the 505(b)(2) Application grouping. As Chemical Class 3 is the second most common Chemical 
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Class application type, further clarification and better communication throughout the pre-NDA 
submission may help to eliminate these unnecessary trials. 
3. Programs Requiring Greater Than Two Clinical Trials 
A central tenant for the approval of new drugs is the replication of evidence supporting 
efficacy. Consequently, it is out of the ordinary for more than two trials to be needed unless the 
applicant is attempting to incorporate claims for multiple indications or populations in the 
labeling. There were nine applications from three different Chemical Classes that completed 
greater than two clinical trials that were ‘positive’ in terms of the statistical and clinical review; 
three applications clearly identified the reasoning behind additional trials (Figure 8).  
Figure 8, Reasons for an Application Requiring                                                            
Greater Than Two Clinical Trials by Chemical Classification 
 
Abbreviations: CR: Complete Response; MI, 
 MP: Multiple Indications/ Multiple Populations; U: Unknown  
 
In these cases, applicants chose to expand their labeling indication or population. For 
example, NDA 205352 Aleve PM (naproxen and diphenhydramine), which completed a total of 
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four Clinical Trials, did so to expand the target population to both adults and children over the 
age of 12, as well as to provide signals of efficacy for two indications: 1) for relief of occasional 
sleeplessness when associated with minor aches and pains and 2) helps you fall asleep and stay 
asleep. Despite the additional development burden, the industry often sees this as a good 
resource investment as it will most likely increase the overall value of the drug once it gets to 
market.  
4. Subject Numbers 
The recruitment of subjects in clinical trials is often a slow and expensive process, with 
vast expenditures going toward site procedural costs, CRO reimbursements, and recruitment 
advertising. Studies that do not spend this money often loose subjects to other, better-supported 
trials at the same sites. As a convention, New Chemical Entities that are going to be dosed 
chronically require 1500 subjects to be exposed to the drug (Food Drug Administration Center 
for Drugs Evaluation Research, 2015). Development programs for where there are prior data 
(e.g., 505(b)(2)s) would be expected to require fewer subjects, special circumstances 
notwithstanding. Consequently, applicants should study enough subjects to acquire adequate 
safety and efficacy support but not burden their programs with studies that do not serve some 
purpose of value. Table 4 demonstrates the number of subjects (mean +/- the standard deviation; 
median) for the positive Phase 2b/3a studies, and the whole clinical development program, by 
test treatment and Chemical Class. In addition, Figure 9 and Figure 10 demonstrate the averages 





Table 4, Average Number of Subjects by Chemical Classification  
Chemical 
Classification 




Treatment + Ph 
2b/3a Trials 





Total in Whole 
Program 
Class 1 (N = 9) 291 ± 367; 191 639 ± 733; 503 549 ± 473; 618 1,080 ± 959; 1,063 
Class 2 (N = 3) 148 ± 256; 0 198 ± 342; 0 307 ± 399; 102 378 ± 522; 102 
Class 3 (N = 32) 222 ± 378; 52 382 ± 522; 249 674 ± 985; 173 813 ± 1,124; 221 
Class 4 (N = 16) 705 ± 796; 476 1,580 ± 1,503; 1,467 
1,511 ± 2,195; 
581 
2,691 ± 3,521; 
1,632 
Class 5 (N = 33) 84 ± 179; 0 140 ± 308; 0 150 ± 239; 0 223 ± 386; 0 
Class 7 (N = 7) 0; 0 0; 0 5 ± 11; 0 8 ± 19; 0 
Abbreviations -  2b=Study used to explore safety and efficacy; 3a=Study used to confirm substantial evidence, a 
‘pivotal trial’; Ph=Development Phase 
 














        Figure 10, Mean Number of Subjects in Whole Program 
 
 
 Chemical Classes 4 and 1 had the highest average number of subject numbers, 
respectively, for positive Phase 2b and Phase 3a trials of adequate design and conduct to be 
considered as Substantial Evidence. The applications with the 5 highest numbers of participants 
were all from Chemical Class 4 drugs. The large number of subjects on the test treatment for 
positive trials and the total program participants for Chemical Class 1 can be explained by the 
fact that a new molecular entity begins with the least amount of known information. Therefore, 
New Chemical Entities frequently require the largest amount of testing and a large number of 
subjects to adequately characterize safety and efficacy. 
The application with the highest number of study participants was a repurposed drug2, 
NDA 200063 Contrave (naltrexone hydrochloride/bupropion hydrochloride), in the Therapeutic 
Class of anti-obesity drugs, most likely due to issues surrounding the safety of the new dosing 
regimen that required extensive study. This application also received a Review Extension for 
safety concerns, and a Complete Response for insufficient cardiovascular safety and 
                                                
2 A repurposed drug is a drug previously approved for a different indication 
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teratogenicity study data. Obesity has much comorbidity that increase the patient’s risk factor for 
many serious conditions, explaining the greater safety concerns surrounding drugs given to this 
population. 
5. Duration of Trials 
One major cost to consider in the clinical development of the drug is the duration of the 
clinical trials. This process can be variable, (i.e. extending enrollment periods due to low 
enrollment numbers) and requires a great deal of resources (monitoring incoming data, site 
inspections, finding sites and clinical investigators etc.). Beyond this variability, there are certain 
factors, for example, disease indication and study design (i.e. cross-over versus parallel) that are 
used to plan the clinical development program trial duration. The table below shows the average 
duration of the trials done for the clinical development program (Phase 2b safety and Phase 3a 
efficacy trials). It would be expected that Chemical Classes 1 and 2 would on average have the 
longest trial durations, because as previously mentioned, most often New Molecular Entities and 
New Active drugs begin clinical development with the least amount of safety and efficacy data. 
Table 5 displays the average duration and standard deviation of the pooled Phase 2b and 3a 
studies done by Chemical Class. 
 
Table 5, Average Duration of Trials by Chemical Classification 
Chemical Classification 
Duration of Phase 2b/3a Studies 
in Weeks (Mean ± Standard 
Deviation) 
Duration of Phase 2b/3a 
Studies in Weeks (Median) 
1 (N = 9) 32.8 ± 51.7 6 
2 (N = 3) 61 ± 0 61 
3 (N = 32) 11.2 ± 13.8 7 
4 (N = 16) 17.5 ± 20.6 8 
5 (N = 33) 15.8 ± 11.4 16 




The five applications with the longest duration in clinical trials were each in different 
Therapeutic Classes and in four different Chemical Classifications, with two applications falling 
into the New Combination, Chemical Class 4. The singe defining characteristic of all of these 
was that they were all for the treatment of chronic conditions. 
6. Waivers, Post Marketing Requirements and Commitments  
Waivers or deferrals may be given to applicants to ease the regulatory burden based on 
prior evidence suggesting an approval would not need to obtain certain data, in the case of 
waivers, or be safe enough, in the case of deferrals, to market the drug prior to obtaining certain 
data. Deferrals are given as either studies “required” to be done post marketing or as a 
“commitment” for the applicant that they will be done during the post marketing phase of 
development. Required post marketing studies have a strict timeline agreed upon at the time of 
approval, which is then monitored by the FDA. 
Five of the 100 SBOAs received Nonclinical waivers, primarily for carcinogenicity 
studies. Eleven applications had Nonclinical Post Marketing Required studies (PMRs) for issues 
such as reproductive and development toxicity, antibody resistance, carcinogenicity, and 
extractability/leachability. Only two of the programs reviewed had Nonclinical Post Marketing 
Commitment studies (PMCs) for issues of impurities and extractability.  
Table 6, Nonclinical Post Marketing Approval Agreements  
Approval Agreement Type % of Applications Specific NC Tests 
Waiver 5 Various Carcinogenicity 
PMR 11 
Reproductive and Development Toxicity; 
Antibody Resistance; Carcinogenicity; 
Extractability/Leachability 
PMC 2 Impurities; Extractability 
*The lists of test are in order, from most common to least common 
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Thirty-eight of the 100 SBOAs received Clinical Pharmacology waivers dealing with 
Bioequivalence or thorough QT studies. Nineteen SBOAs had Clinical Pharmacology PMR 
studies for a variety of reasons, though pediatric PK and drug interactions were the most 
common. Only one SBOA had a Clinical Pharmacology PMC study dealing with dissolution 
methodology.  




Applications Specific CP Tests 
Waiver 38 Biowaiver; QT 
PMR 19 
Pediatric PK; Drug Interaction; Renal 
Impairment; QT; Alcohol Interaction;  Dose 
Linearity; Bioequivalence; Food Effect; In Vitro 
ADME; Hepatic Impairment 
PMC 1 Dissolution Method 
*The lists of test are in order, from most common to least common 
Sixty-three of the 100 SBOAs received Clinical waivers, almost entirely dealing with the 
need for pediatric studies. Full Pediatric waivers were, in most cases, given when the indication 
was not present in the pediatric population. Partial pediatric waivers were given in cases where 
partial pediatric labeling was able to be included in the referenced material, therefore the waiver 
was given for a subset of the pediatric population for which there was no reference information 
available. Thirty-five SBOAs had Clinical PMR studies, where pediatrics, again, was the 
predominant issue, but with a number of other types of long-term safety issues also resulting in 
PMRs. For Pediatric studies under post marketing requirements, most often the cases were 
similar to those of clinical waivers, when the pediatric labeling was included in the reference 






Table 8, Clinical Post Marketing Approval Agreements  
Approval Agreement Type % of Applications Specific Clinical Tests 
Waiver 63 Partial Pediatric; Full Pediatric; Maternal Labeling 
PMR 35 
Pediatric; Long Term Safety and Efficacy; 
Post Marketing Other; Post Marketing Abuse 
Liability; Cardiovascular Outcome Trial 
PMC 1 Long Term Safety and Efficacy 
*The lists of test are in order, from most common to least common 
Pediatric PMR may have also been indicated for drugs that were ready for approval in 
adults but not yet in children. In this this situation, delaying the approval of the drug would be 
considered unethical to the adult population. In contrast, post market commitments were rarely 
seen. Only one SBOA had a Clinical PMC study for a long-term safety study The most common 
Clinical waivers were either Partial Pediatric or Full Pediatric waivers. This is most likely 
because post marketing commitments are studies that the applicant has agreed to complete, but 
which are not required by law (FDA, 2016c). 
7. Timeline and Duration of Development Program  
The Duration of the Lifecycle Development Program, for the purpose of this project has 
been defined as:     Approval Date - Initial IND Submit Date  
The duration of the lifecycle development can be used to fully understand both the time 
and regulatory burden of a given drug. However, because INDs may begin at vastly different 
stages (e.g., at a first-in-human study for a New Chemical Entity and with only a BE study for a 
reformulation), interpretation of an analysis of the duration between initial IND submission and 
the drug Approval Date can be complicated. It is, at least, more common that drugs of the same 
Chemical Class submit their INDs at similar stages and so for the purpose of this study, the 
duration of the development program is explained from the perspective of the Chemical Class. 
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Not surprisingly, the average for lifecycle development programs requiring clinical trials 
is longer than those programs where no trials were needed. Review Extensions and Complete 
Responses seem to be associated with a similarly long lifecycle development period, despite the 
three-month extension versus ten-month (plus time to rectify the deficiency) delay period 
associated with each. This seems to be because over half of the applications receiving a review 
extension (56%) also received a complete response. Table 9 demonstrates the duration (IND 
Submit date to Approval Date)  ± standard deviation of development programs with or without 
clinical trial requirements by regulatory outcome delay type. 
Table 9, Average Duration of Lifecycle Development, With and Without Clinical Trials 
 Duration of Lifecycle Development 







Review Extension Complete Response 
No Clinical 
Trials 
1,391 ± 940; 
1302 
1,279 ± 430; 
1215 
1,567 ± 1,169; 
1086 
1,384 ± 688; 1159 
At Least One 
Clinical Trial 
2,159 ± 1,465; 
1850 
NA 2,711 ± 2,172; 
1972 
2,725 ± 1,150; 2669 
 
*See appendix D for graph of the individual applications comprising this data.  
 
There seems to be little to suggest, at this point in the analysis of these data, any single 
underlying cause for having a particularly protracted development program. Interestingly, the 
applications with the three longest clinical development lifecycles came from three different 
Chemical Classes. They each completed between one and two clinical trials, and in addition, 
they all received a review extension at some point during their initial NDA submission to their 
applications for different reasons. The second and third longest critical lifecycle development 
durations were among the applications approved past the PDUFA Goal Date, by 148 and 23 
days, respectively. Aside from this, the applications had little in common, being reviewed by 
different Divisions, falling into three different Purposes for 505(b)(2) categories, Therapeutic 
 
35	
Classes and ATC2 Codes. Further evaluation of this issue should be pursued in the remaining 
505(b)(2) SBOAs. 
D. Regulatory Review  
1. General Observations 
The applications with the four shortest review durations, all less than 55 days had each 
received a Complete Response prior to the final application submission. The short duration of 
their regulatory review is likely because the Agency was able to review the drug rapidly because 
they had already reviewed the majority of the material and therefore only needed to review the 
additional material that had been submitted with the Complete Response.  
Figure 11, Duration of the Regulatory Review Period
 
*The standard Review Period (270 Days) is given as a point of reference **The timeline is not drawn to scale 
The three longest review periods were 542 days, 481 days, and 409 days versus the 
standard 270 days for a review for a Standard Review cycle. All three were from different 
Therapeutic Classes, ATC2 codes, and reviewed by different Divisions; however, as a single 
point in common, they each had a Review Extension for a Major Amendment.  
2. Priority Versus Standard Regulatory Review Cycle 
When evaluating the Review Cycle for NDAs submitted to the FDA, one should consider 
applications with a Priority Designation separately from those with a Standard Review status. 
The review designation of Priority was established in the 2007 as an amendment to the Food 
Drug and Cosmetic Act to help expedite the review of needed medications. A Priority 
designation means that the drug will be reviewed with a 6 month/180 day, versus the Standard 
 
36	
application 9 month/270 day review cycle.  
Figure 12, Expected Priority Regulatory Review Versus the Standard Regulatory Review Period 
 
*The timeline is not drawn to scale 
The average regulatory review cycle (Final NDA Submit Date to Approval Date) is 
232.26 days (standard deviation: 89.40) for Priority reviews and 246.74 days (standard 
deviation:102.44) for Standard reviews, respectively.  
Figure 13, Average Priority Regulatory Review Versus the Standard Regulatory Review Period, 
from 100 SBOA Dataset 
 
*The timeline is not drawn to scale 
The similarity in the mean duration of the regulatory review period for priority and 
standard reviews is not what one would expect. This issue should be further explored. 
Particularly of interest would be further exploration of the standard applications with the shortest 
Regulatory Review duration and the priority applications with the longest Regulatory Review 
duration.   
3. Applications Approved Past PDUFA Goal Date  
Having a Review Cycle run past the PDUFA goal date is highly unusual since the 
Agency is accountable to Congress for these metrics and since Application deficiencies would 
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typically result in a Complete Response before such a milestone was missed. Rather, this is more 
likely to occur in the setting of an almost certain approval that needed a Class REMS (Risk 
Evaluation and Mitigation Strategy) or some other unusual circumstance. Six percent of the 
applications reviewed in this project were approved past their PDUFA Goal date. The number of 
days that the applications were approved past their goal date ranged from 11 to 238 days.  
Figure 14, Visual Representation of Applications Approved the  
Furthest After Their PDUFA Goal Date 
 
*The five applications highlighted with an orange ring were the approved  
the latest after their PDUFA goal date 
**In the above figure “0” days indicates the PDUFA goal date 
Three of the drugs approved past their PDUFA goal date belong to the class of extended 
release drugs, two of which are also abuse-deterrent. These extended release opioids were also 
approved at a time when the FDA was working with Sponsors to develop the Risk Evaluation 
and Mitigation Strategy before approving any Extended-Release and Long Acting (ER/LA) 
opioids to help combat opioid misuse and diversion (FDA, 2016d). The current and growing 
problem of opioid dependence within the United States, has largely been created by the overuse 
and over prescribing of opioid pain medication, often for indications not needing such high-
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strength and long acting opioids. Approving abuse deterrent versions of opiate medications is 
one format the FDA is using to combat this problem.   
4. Applications Approved Before PDUFA Goal Date 
While the reviewer workload, multidisciplinary nature of the review protocol, and 
volume of information in a typical NDA preclude finishing review much sooner than the PDUFA 
goal date, this can occur on occasion. On at least 5 occasions from the 100 SBOAs reviewed, 
drugs were approved significantly sooner (i.e., from 63 days to 166 days) than their Goal Date.  
 
Figure 15, Visual Representation of Applications Approved the  
Furthest Before Their PDUFA Goal Date 
 
*The five applications highlighted with an orange ring were the applications 
 approved with the greatest amount of time before their PDUFA goal date 
**In the above figure “0” days indicates the PDUFA goal date 
Three drugs approved before their PDUFA Goal date are indicated for emergent and 
serious medical conditions. One is a class 5 medication for Cardiac therapy, approved for 
Ophthalmologic use, for the indication of pupil dilation. Two of the 5 drugs approved soonest 
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before their Goal date belong to the Therapeutic Class of opioid antagonist and were approved 
78 days and 63 days before their Goal date for the indication of emergency treatment of 
suspected opioid overdose. Notably, these were the only two of the top five drugs approved 
before their Goal date that received both priority and fast track designations for indications 
involving the administration of emergency and lifesaving medication. Given this knowledge, it is 
reasonable to conclude that often times, 505(b)(2) drugs approved before their PDUFA Goal date 
are potentially of high value to society. 
E. Regulatory Outcomes 
1. Trends in Regulatory Outcomes in Recent Years   
During the progression of the most recent period from 2013 to 2015, there was a decrease 
in the percent of applications reviewed for this project to date, filed that year, encountering 
Refuse to File (7% of all applications), reported as 17%, 9%, and 3% for 2013, 2014 and 2015 
respectively. This same trend was identified for Review Extension (32% of all applications), 
which adds three months to the Review Period for the application; Review Extension affected 
61% of applications in 2013, 28% in 2014, and 13% in 2015.  
This dramatic reduction of the percentages of applications encountering Refuse to File and 
Review Extension by roughly half that of the previous year could be interpreted as an increased 












Figure 16, Distribution of the Number of Applications Encountering (Y) or Not 
Encountering (N) Each Type of Regulatory Delay by Year of Approval 
 
*The numbers labeling the bars correspond to the total number of applications represented in that bar. 
Because there were uneven samples taken from each of the years (focusing on reviewing the most current 
data), the graph depicts the inequalities between years. 
 
However, for Complete Responses, the most frequently encountered delaying regulatory 
outcome, recent years (2013-2015) do not show this overall trend, with the exception of when 
grouped by Chemical Classification in some of the more popular Chemical Classification groups 
(e.g. Chemical Class 3). The fact that this trend is not seen for the Complete Response, the most 
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commonly encountered regulatory outcome (38% of all applications) indicates that better 
information is needed to understand what can cause Complete Responses and how to avoid them. 
This adds upon the information discussed earlier relating to lifecycle development duration and 
delaying regulatory outcomes (VII.C.7), and will be discussed in further detail in the section 
pertaining to the delay period (VII.E.2). 
2. Delay Period 
The delay period is defined as: 
Final NDA Submission Date - Initial NDA Submission Date (Appendix A) 
The delay period was determined for applications having encountered one or more of these three 
outcomes: Refuse to File, Review Extension and Complete Response. The number of 
applications, of the total 100 SBOA dataset which received a Complete Response was 38, 32 
received a Review Extension, and 7 Received a Refuse to file.  







Refuse to File 
(RTF) 
Class 1 1 3 0 
Class 2 2 3 0 
Class 3 12 12 2 
Class 4 6 3 0 
Class 5 15 9 3 
Class 7 2 2 2 
TOTAL 38 32 7 
 
It was not uncommon for applications to encounter more than one type of regulatory 
outcome known to cause delays. Over half (53%) of the 100 SBOAs reviewed, were applications 
which had encountered at least one delaying regulatory outcome. Of that percentage, almost 36% 
(19 applications) were instances where the applications had encountered more than one delaying 
regulatory outcome.  
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Figure 17,  Absolute Number of Applications Encountering One or More of Each Delaying 
Regulatory Outcome
 
*N = 100 SBOA Database, of this 53 applications encountered at lest one type of delaying regulatory outcome and 
are represented in this figure  
 
a) Complete Response 
 
For the purposes of this study, the delay period from a Complete Response was defined 
as the period from an NDA’s initial submission to it’s final submission, for NDAs that had 
received a Complete Response, regardless of the number of Complete Response cycles the 
application encountered. The average delay for an application receiving a Complete Response 
was 781 days (standard deviation: 487; median: 643), versus the average delay period of 16 days 
(standard deviation: 80; median: 0) for those applications that did not encounter a Complete 
Response.  
The four most common causes contributing to a Complete Response action were 
chemistry concerns (17 applications), insufficient/inadequate safety or efficacy data (16 








Table 11, Most Common Causes of Encountering a Complete Response 
Cause of Complete Response Number of Applications with this Cause 
Chemistry Concerns 17 
Insufficient/Inadequate Safety or Efficacy Data 16 
Tentative Approval 8 
Manufacturing Concerns 6 
 
The cause associated with the application having the longest delay period were those 
involving the combination of manufacturing and chemistry concerns, which was associated with 
an average delay period of 1159 days (standard deviation: 841) and was the type of delay that 
was most frequently encountered by the Chemical Class 3 and 5 drugs. 
b) Review Extension 
 
A Review Extension is a 3-month extension of the review cycle based on receipt of 
additional materials that are needed for approval. Review Extensions are generally not given to 
programs unless an Approval is anticipated since the Application could simply receive a 
Complete Response for deficiencies and would be spared a 3-month delay. The average review 
cycle duration for an application encountering a Review Extension was 433 days (standard 
deviation: 546; median: 296), versus the average review period for those applications that did not 
encounter a Review Extension, 250 days (standard deviation: 441; median: 0), although some of 
the programs may have encountered other regulatory outcomes resulting in delays. As mentioned 
in the Section pertaining to the Lifecycle Development duration, the fact that over half the 
applications encountering Review Extensions also received at least one Complete Response most 
likely has an influence on the average delay period duration being greater than the expected 90-
day (3-month) duration. 
The four most common causes for review extensions were chemistry concerns (8 
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applications), late submission of new data (11 applications), manufacturing concerns (4 
applications), insufficient/inadequate safety or efficacy data (4 applications). 
Table 12, Most Common Causes of Encountering a Review Extension 
Cause of Review Extension Number of Applications with this Cause 
Late Submission of New Data 11 
Chemistry Concerns 8 
Manufacturing Concerns 4 
Insufficient/Inadequate Safety or Efficacy Data 4 
 
Causes associated with the longest delay period were those involving safety concerns 
related to REMS requirements, which was associated with an average delay period of 791 days 
(standard deviation: 187). This type of delay was most frequently encountered by the Purpose of 
the 505(b)(2) Application category of Repurposed drugs. 
c) Refuse to File  
 
The FDA may refuse to file (review) an NDA that has been submitted based on the 
regulations codified in 21CFR314.101(d)(1-9) (Food and Drugs, 2016). This action must take 
place within 60 days of the application being filed, and can be for various reasons all of which 
aim at avoiding multiple submission cycles and unnecessary review of an incomplete application 
or Abbreviated NDAs which were incorrectly submitted as an NDA (Office of New Drugs, 
2013). The average duration of the review cycle for an application encountering a Refuse to File 
was 615 days (standard deviation: 420; median: 483), versus the average period for those 




The three causes for a refuse to file an application were chemistry concerns (3 
applications), the applicant not including a fee with their submission (2 applications), and 
insufficient/inadequate safety or efficacy data (2 applications). 
Table 13, Most Common Causes of Encountering a Refuse to File 
Cause of Refuse to File Number of Applications with this Cause 
Chemistry Concerns 3 
No Fee Included 2 
Insufficient/Inadequate Safety or Efficacy Data 2 
 
The cause associated with the longest delay period were those in the category involving 
insufficient or inadequate data which was associated with an average delay period of 943 days 
(standard deviation: 651). This type of delay was most frequently encountered in SBOAs of 
Chemical Class 5 drugs. 
The applications experiencing the longest delay periods had received at least one 
Complete Response. The applications with the first (1943 days) and fourth (1673 days) longest 
delays received two complete responses, for manufacturing concerns and insufficient data related 
to safety concerns, respectively. The application with the second longest delay period (1793 
days) received one Complete Response related to manufacturing concerns. The third longest 
delay period (1754 days) received four Complete Responses, related to manufacturing concerns 
and chemistry concerns. Additionally, the applications with the third and fourth longest delay 
periods each received a review extension in addition to their Complete Responses. Enhancing 
communication between the agency and applicant during the pre-NDA stage of the development 
lifecycle could help to reduce the frequency of the complete response actions. 
The trend seen over the recent years with decreasing percentages of Review Extensions 
and Refuse to Files encountered per year could be due to improvement in the industry, although 
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the change could be caused in part by a decreased tendency in the Agency to utilize these severe 
regulatory actions and increased pressure to approve drugs (see Figure 16, page 48). Considering 
that Complete Responses are associated with a longer duration of time between the initial NDA 
submission and the final NDA submission than either Refuse to File or Review Extension, the 
pharmaceutical industry should focus its efforts on better understanding the causes of their 
Complete Responses and how to decrease the likelihood of receiving Complete Responses.  
VIII. Limitations 
This study did not take into account the overall value of the drug and how that could 
influence the importance of the duration of approval time/review time/delays. Often time the 
overall value of a drug can impact all the stakeholders involved, including the Agency and the 
Sponsors. The specific effects of these influences are often unknown and unable to be accounted 
for, making it difficult to draw a concrete conclusion even with knowledge of this phenomenon.  
 The data included focuses mainly on the most recently submitted applications. The 
majority of the database is composed of applications from the 2014 and 2015. Additionally, of 
the 277 505(b)(2) applications, 250 were available for review, due to the time constraints of the 
project 100 applications were randomly selected from the available 250, to provide adequate 
inferential information. Although the database is not comprehensive, this was chosen as the 
preferred method to provide information on the most current and relevant submissions.  
 The data collected for this study was based on reviewer information. Occasionally, 
conflicting information between different departments or reviewers was encountered and best 
judgment was used to decide the final information. Additionally, reviews are not all inclusive 
documents and in a select number of rare instances, the SBOAs do not include all the standard 
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sections. Lastly within the SBOAs certain information is often blacked out for legal reasons but 
in a select handful of applications may have contained one or more of the variables in the 
database (most frequently IND submission date). 
 Not all data could be included in the simple descriptive statistics used in this study. For 
example, in certain instances, Chemical Classification can be a combination of two Chemical 
Classes, for these cases the representative Chemical Classification was chosen by taking into 
account the Purpose of the 505(b)(2) Application categorization. This method was chosen as it 
resulted in the representative Chemical Class reflecting the driving of the application. This also 
allowed for analysis of the Chemical Classes within variation instead of creating individual 
Chemical Class categories based on a very small number of applications.	
IX. Conclusion 
In this Section, I note what I believe are the most important contributions of the 505(b)(2) 
to regulatory strategy as well as some observations I found most unexpected.   
Utilization of the 505(b)(2) application as a portfolio strengthening strategy yields many 
benefits with few risks. The unique characteristic of the 505(b)(2) application is that is can allow 
one to mitigate risk and resource expenditure while maintaining the potential to participate in 
Expedited Programs (e.g. the highly coveted Orphan drug exclusivity). In practice, this means 
that resources can be allocated elsewhere, in development programs of other drugs with a higher 
resource burden. The ability to “play it safe” while still “playing the lottery” makes the 505(b)(2) 
a valuable strategy when utilized correctly. 
The data suggest that there is little difference in the duration of the Regulatory Review 
periods between Standard and Priority applications. This unexpected finding should be explored 
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in much greater detail, beyond the level of encountering at least one type of delaying regulatory 
outcome. 
Because many regulatory outcomes resulting in delays dealt with the same concerns, it is 
reasonable to suggest that Sponsors focus on strengthening their manufacturing practices, 
preparing for production facility inspections, and dealing with CMC (Chemistry) issues of novel 
formulations. This seems an inherently intuitive rule, but it is particularly important for 
applications submitted under 505(b)(2) for approval. Often times, references used by programs 
using the 505(b)(2) approval route lessen the burden of providing evidence of safety and 
efficacy. Therefore, manufacturing and CMC concerns become the most complex and critical 
problems encountered during the development process. The knowledge gained by developing 
better CMC and manufacturing practices has the potential to positively impact the development 
of drugs outside of the 505(b)(2) pathway. 
It is expected that the Agency’s past findings of safety and efficacy are the most common 
types of references. As more drugs become approved, the amount of available information to 
reference will only increase. This has the potential to greatly increase the utilization of the 
505(b)(2) pathway within the pharmaceutical industry. 
Given the distinct benefits and potential impact from using the 505(b)(2) regulatory 
strategy, the pharmaceutical industry should strive to more efficiently and effectively utilize it. 
This can be achieved through better communication and increased collaboration between the 
Agency and Sponsors. This could be especially beneficial throughout the duration of the pre-
NDA submission phase of lifecycle development program, leading to benefits for both the 
Sponsor and Agency. The chance for the Agency to help Sponsors better understand when and 
why they are encountering a particular delaying regulatory outcome could provide the Sponsors 
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more time to prepare and to resolve the problems. This, in turn, could decrease the strain put on 
the Agency by multiple review cycles of a drug application. Additionally, increased retrospective 
communication, once the application has been approved, between the Agency and Sponsors 
could grant the Sponsors a chance to better understand why the delaying regulatory outcome 
occurred during the submission process. This would help Sponsors to preempt future delays of 
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Appendix A: Variable Breakdown 
1 APPLICATION NUMBER 
2 Priority Standard (P/S) 
3 Fast Track (Y/N) 
4 Accelerated Approval (Y/N)  
5 Orphan Status (Y/N) 
6 Breakthrough (Y/N/NA) 
7 QIDP (Y/N/NA) 
8 Established Name (free text) 
9 Trade Name (free text) 
*10 Year of Approval (2010/2011/2012/2013/2014/2015) 
11 Molecular Class (text) 
12 ATC4 Code (text) 
*13 Therapeutic Class (text)  
*14 ATC2 Code (text) 
15 Combination Products (FDC/CDDP/N) 
16 Formulation (P/Po/O/S/Sa/T/To) 
17 Modified or Immediate Release (C/D/E/I/S) 
18 Route of Administration (H/I/IM/O/P/Pa/SQ/Su/T) 
19 Indication (free text) 
20 Applicant (free text) 
21 Division (text) 
 
54	
22 IND# (#)  
23 IND Submitted (MM/DD/YYYY) 
24 Initial NDA Submission (DD/MM/YYYY) 
25 Withdrawal or RTF (Y/N) 
26 RTF Reason (text) 
27 Final NDA/CR Submitted (DD/MM/YYYY) 
28 Review Extension? (Y/N) 
29 RE Reason (text) 
30 Complete Response? (Y/N) 
31 # of CRs? (#) 
32 Expanded CR Reasons; Reason for Each Cycle (text) 
33 CR Reason (text) 
34 Initial PDUFA Goal Date (DD/MM/YYYY) 
35 Final PDUFA Goal Date (DD/MM/YYYY) 
36 Approval Date (DD/MM/YYYY) 
37 Was Approval Date After the Final PDUFA? (Y/N) 
38 Approval Date – PDUFA Goal Date (in # of days) 
39 Reason Approved After PDUFA Goal Date (NA or text) 
40 Type of Pediatrics Evidence? (text) 
41 Type of Geriatrics Evidence? (text) 
*42 Chemical Classification (#) 




44 Referencing Nonclinical? (Y/N) 
45 Nonclinical References (L/M/P/NA) 
46 Was a Receptor Binding Screen Done? (Y/N) 
47 Was a Single Dose Toxicity Study Done? (Y/N) 
48 Was a 6 Month Rodent Repeat Dose Toxicity Study Done? (Y/N) 
49 Was a 9 Month Rodent Repeat Dose Toxicity Study Done? (Y/N) 
50 Complete set of Toxicology Studies (prior 3) Done? (Y/N) 
51 If 6MO rodent OR 9 MO non rodent RDT were not done, What was longest Repeat Dose tox 
study done? (text) 
52 Was an Ames study done? (Y/N) 
53 Was a Micronuclease study done? (Y/N) 
54 Was a chromosomal aberration study done? (Y/N) 
55 Complete set of gene tox studies (prior 3) Done? (Y/N) 
56 Was A CV Safety Pharm study done? (Y/N) 
57 Was a respiratory safety pharm study done? (Y/N) 
58 Was a CNS safety pharm study done? (Y/N) 
59 Was a complete set of Safety Pharm studies (prior 3) done? (Y/N) 
60 Was a Fertility and early embryonic study (Segment 1) study done? (Y/N) 
61 Was a Embryo-fetal development study done (Segment 2) study done? (Y/N) 
62 Was a postnatal development study done (segment 3) study done? (Y/N) 
63 Complete set of repro tox studies (prior 3) done? (Y/N) 
64 Was a CARC program done at all? (Y/N) 
65 Carc with 1 or 2 species? (NA/1/2) 
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66 Was a juvenile study done? (Y/N) 
67 Were any abuse liability studies done (Animals)? (Y/N) 
68 Any other P/T studies? (Y/N) 
69 Type of special P/T study (free text) 
70 Was there a NC PMR at approval? (Y/N) 
71 Type of PMR NC (text) 
72 Was there NC PMC at approval? (Y/N) 
73 Type of NC PMC (text) 
74 NC Waiver? (Y/N) 
75 Which P/T Study Waived? (text) 
CLINICAL PHARMACOLOGY  
76 Referencing Clinical Pharmacology? (Y/N) 
77 Clinical Pharmacology References (L/M/P/NA) 
78 Was an SAD study done? (Y/N) 
79 Was an MAD study done? (Y/N) 
80 Was a MTD (maximal tolerated dose) determined? (Y/N) 
81 Was a SD study done? (Y/N) 
82 Was a MD study done? (Y/N) 
83 Was a Relative bioavailability study done? (Y/N) 
84 Was a dose proportionality study done? (Y/N) 
85 Was a food effect study done? (Y/N) 
86 Was a renal impairment study done? (Y/N) 
87 Was a hepatic impairment study done? (Y/N) 
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88 Was a Ped Pk study done? (Y/N) 
89 Was an elderly study done? (Y/N) 
90 Was a gender study done? (Y/N) 
91 Was IN VITRO ADME done? (Y/N) 
92 Was IN VITRO DDI done? (Y/N) 
93 Was IN VIVO DDI done? (Y/N) 
94 Was a QT study done? (Y/N) 
95 Was a mass balance study done (In vivo)? (Y/N) 
96 Was a Population PK study done? (Y/N) 
97 What was derived from the PPK (text) 
98 Was an Abuse Liability Study Done (Humans)? (Y/N) 
99 Was an In vivo Alcohol interaction study done (in humans)? (Y/N) 
100 Type of special CP study? (free text) 
101 Was there a CP PMR at approval? (Y/N) 
102 Type of PMR CP (text) 
103 Was there CP PMC at approval? (Y/N) 
104 Type of CP PMC (text) 
105 CP Waiver? (Y/N) 
106 Which CP Study Waived? (text) 
CLINICAL 
107 Referencing Clinical? (Y/N) 
108 Clinical References (L/M/P/NA) 
109 Clinical Requirements? (Y/N) 
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110 Was there a C PMR at approval? (Y/N) 
111 Type of C PMR (text) 
112 Was there C PMC at approval? (Y/N) 
113 Type of C PMC (text) 
114 # Ph2b Trials Performed (#) 
115 # + Ph2b Trials (#) (NA or #) 
116 Average Duration of Treatment Period for + Ph2b Trials (weeks) (NA or #) 
117 # Ph3a Trials Performed  
118 # + Ph3a Trials (NA or #) 
119 Total # + Ph2b/Ph3a Trials (NA or #) 
120 Average Duration of Treatment Period for + Ph3a Trials (weeks) (NA or #) 
121 # OLES or Safety Trials (#) 
122 # Other Trials (#) 
123 Type of Other Trials (NA or text) 
124 Total # subjects in + Ph2b/3a trials (not including OLES) 
125 # subjects on test treatment in Ph2b or 3a efficacy program (not including OLES) 
126 # subjects on test treatment in whole program (NA or #) 
127 # subjects in total program (NA or #) 
128 Type of + Ph2b/3a controls (AN/AS/H/P/S) 
129 C Waiver? (Y/N) 
130 Which C Study Waived? (NA or text) 
131 If DS > 2; Comment here. (NA or text) 
132 If DS = 0; comment on reason (NA or text) 
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133 Summary Review identified studies essential to approval for efficacy? (Y/N) 
134 Types of studies and # (NA or text) 
135 Delay? (Y/N) 
Timeline Columns Derived from Original Data: 
Duration of the Lifecycle Development Program: Approval Date (36) – Initial IND Submit Date 
(23) 
Duration of the Regulatory Review Cycle: Approval Date (36) – Final NDA Submit Date (27)  















Appendix B: Full List of ATC2 Codes with Frequencies (46 Total) 
1 Agents acting on the renin-angiotensin system: 2 
2 Agents acting on the renin-angiotensin system/calcium channel blockers: 1 
3 All other therapeutic products: 2 
4 Analgesics: 3 
5 Analgesics/Analgesics: 1 
6 Anti-acne preparations: 1 
7 Antibacterials for systemic use: 8 
8 Antibacterials for systemic use/antibacterials for systemic use: 1 
9 Antidiarrheals, intestinal anti-inflammatory/anti-infective agents: 1 
10 Antiepileptics: 4 
11 Antifungals for dermatological use: 1 
12 Antigout preparations: 1 
13 Antihistamines for systemic use/Corticosteroids, dermatological preparations: 1 
14 Antiinflammatory and antirheumatic products: 4 
15 Antiinflammatory and antirheumatic products/Antihistamines for systemic use: 1 
16 Antineoplastic agents: 8 
17 Antiobesity preparations, excluding diet products: 1 
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18 Antithrombotic agents: 2 
19 Antivirals for systemic use: 2 
20 Beta blocking agents: 2 
21 Bile and liver therapy: 1 
22 Blood Substitutes and perfusion solutions: 1 
23 Calcium channel blockers:1 
24 Calcium homeostasis: 2 
25 Cardiac therapy: 3 
26 Contrast media: 1 
27 Cough and cold preparations: 4 
28 Cough and cold preparations/antihistamines for systemic use: 3 
29 Drugs for constipation: 1 
30 Drugs for treatment of bone diseases: 1 
31 Drugs used in diabetes: 3 
32 Mineral supplements: 1 
33 Muscle relaxant: 2 
34 Nucleoslide: 1 
35 Ophthalmologicals: 6 
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36 Other alimentary tract and metabolism products: 1 
37 Other dermatological preparations: 1 
38 Other nervous system drugs: 2 
39 Otologicals: 1 
40 Pancreatic hormones: 1 
41Psychoanaleptics: 7 
42 Psycholeptics: 3 
43 Sex hormones and modulators of the genital system: 2 
44 Sex hormones and modulators of the genital system/sex hormones and modulators of 
the genital system/antianemic preparations: 1 
45 Topical products for joint and muscular pain: 1 










Appendix C: Full List of Therapeutic Classes with Frequencies (46 Total) 
1 Analgesics: 11 
2 Anti-acne preparations: 1 
3 Antiarrhythmics: 1 
4 Antibiotic: 10 
5 Anticoagulant: 2 
6 Antidepressant: 2 
7 Antiepileptics: 4 
8 Antifungal: 1 
9 Antigout preparations: 1 
10 Antihistamine/anti-inflammatory: 1 
11 Antihypertensive: 3 
12 Antiinflammatory: 1 
13Antimuscarinic: 1 
14 Antineoplastic: 8 
15 Antiobesity drug: 2 
16 Antiosteoporotic: 1 
17 Antiparasitic: 1 
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18 Antipsychotic: 2 
19 Antitussive/antihistamine: 3 
20 Antitussive/expectorant: 2 
21 Antiviral: 2 
22 Beta-adrenergic receptor antagonist: 1 
23 Bile acid: 1 
24 Blood glucose lowering agents: 4 
25 Bone-vitamin D: 2 
26 Calcium channel blocker: 1 
27 CNS stimulant: 4 
28 Cystine depleting agent: 1 
29 Gastrointestinal motility inhibitor: 1 
30 Hormonal contraception: 1 
31 Hormone replacement: 1 
32 Hypnotic: 2 
33 Laxative: 1 
34 Muscle relaxant: 2 
35 Neuromuscular blocker inhibitor: 1 
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36 NSAID/Sleep aid: 1 
37 Nutrient: 2 
38 Ophthalmics: 3 
39 Opioid antagonist: 2 
40 Opioid replacement therapy: 1 
41 Oral solution for GI tract opacification: 1 
42 Phosphate binder: 1 
43 Replacement therapy: 1 
44 Sympathomimetic: 4 











Appendix D: Duration of Lifecycle Development (in Days) for Applications With (Y) or 
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